With his 62nd birthday looming next month, the science of anti-aging isn’t just another throw of the dice for British investor Jim Mellon.
“We could do with the technology ourselves,” he says on behalf of the experienced execs leading Juvenescence, Mellon’s upstart biotech venture. And he’s not just thinking about another good 40 or 50 years. Instead, he and the Juvenescence team are talking about moving the goal posts of life to 150, cracking the biological barriers that have formed a brick wall at 120.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,200+ biopharma pros who read Endpoints News by email every day.Free Subscription